Frequency of anticancer drug use at the end of life: a scoping review

• Endre Szigethy ^[1] ; Rosario Dorantes ^[2] ; Miguel Sugrañes ^[1] ; Meisser Madera ^[3] ; Ivan Sola ^[1] ; Gerard Urrútia ^[1] ; Xavier Bonfill ^[1]
  1. [1] Universitat Autònoma de Barcelona

     Universitat Autònoma de Barcelona

     Barcelona, España

     
  2. [2] Parc de Salut MAR

     Parc de Salut MAR

     Barcelona, España

     
  3. [3] Universidad de Cartagena

     Universidad de Cartagena

     Colombia

     

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 1, 2024, págs. 178-189
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Anticancer drug use at the end of life places potential extra burdens on patients and the healthcare system. Previous articles show variability in methods and outcomes; thus, their results are not directly comparable. This scoping review describes the methods and extent of anticancer drug use at end of life.

    Methods Systematic searches in Medline and Embase were conducted to identify articles reporting anticancer drug use at the end of life.

    Results We selected 341 eligible publications, identifying key study features including timing of research, disease status, treatment schedule, treatment type, and treatment characteristics. Among the subset of 69 articles of all cancer types published within the last 5 years, we examined the frequency of anticancer drug use across various end of life periods.

    Conclusion This comprehensive description of publications on anticancer drug use at end of life underscores the importance of methodological factors when designing studies and comparing outcomes.